Literature DB >> 29392065

Possible Ototoxic Effects of Topical Rifamycin Application: An Electrophysiological and Ultrastructural Study.

Cihan Abaylı1, Yusuf Kul1, Muhsin Koten1, Ahmet Rıfat Karasalihoğlu1, Abdullah Taş1, Recep Yağız1, Erdoğan Bulut2.   

Abstract

OBJECTIVE: This study aimed to investigate possible ototoxicity associated with topical rifamycin application via electrophysiological tests and ultrastructural examinations.
METHODS: Electrophysiological assessment was performed with tympanometry, auditory brainstem response (ABR), and distortion product otoacoustic emission (DPOAE) measurements. This study was conducted on 40 ears of 20 guinea pigs that were detected to have normal hearing thresholds. The animals were randomly assigned to three groups: Group 1 (n=12) received 0.1 mL rifamycin, Group 2 (n=8) received 0.1 ml gentamycin, and Group 3 (n=20) received 0.1 mL physiological saline. The antibiotics and saline solutions were administered via intratympanic injections. After five injections every other day, electrophysiological tests were performed again on the 15th day. After electrophysiological measurements, the temporal bones of all guinea pigs were prepared for ultrastructural examinations and the cochlear surface morphology was examined by scanning electron microscopy (SEM).
RESULTS: The animals in group 3 did not show a statistically significant change in their DPOAE signal/noise ratio (SNR) or ABR thresholds (p>0.05). In groups 1 and 2, the reduction in the DPOAE SNR and the increase in the ABR threshold were statistically significant (p<0.05). Regarding SEM examination results, the animals in groups 1 and 2 showed statistically significant outer hair cell damage and cochlear degeneration due to the ototoxic effect of the drugs (p<0.05), whereas the animals in group 3 showed no significant damage (p>0.05).
CONCLUSION: The results indicate that rifamycin application to the middle ears of guinea pigs has mild ototoxic effects on their inner ears.

Entities:  

Keywords:  Rifamycin; auditory brainstem response; guinea pig; otoacoustic emission; ototoxicity; scanning electron microscopy

Year:  2017        PMID: 29392065      PMCID: PMC5782998          DOI: 10.5152/tao.2017.2391

Source DB:  PubMed          Journal:  Turk Arch Otorhinolaryngol        ISSN: 2667-7466


  18 in total

1.  Clinical testing of distortion-product otoacoustic emissions.

Authors:  B L Lonsbury-Martin; M J McCoy; M L Whitehead; G K Martin
Journal:  Ear Hear       Date:  1993-02       Impact factor: 3.570

2.  Audiologic threshold monitoring of patients receiving ototoxic drugs. Preliminary report.

Authors:  W L Meyerhoff; G E Maale; W Yellin; P S Roland
Journal:  Ann Otol Rhinol Laryngol       Date:  1989-12       Impact factor: 1.547

3.  ABR evaluation of ototoxicity in cancer patients receiving cisplatin or carboplatin.

Authors:  A De Lauretis; B De Capua; M T Barbieri; L Bellussi; D Passàli
Journal:  Scand Audiol       Date:  1999

Review 4.  Clinical application of otoacoustic emissions: what do we know about factors influencing measurement and analysis?

Authors:  J W Hall; J E Baer; P A Chase; M K Schwaber
Journal:  Otolaryngol Head Neck Surg       Date:  1994-01       Impact factor: 3.497

Review 5.  Audiologic monitoring for ototoxicity.

Authors:  K C Campbell; J Durrant
Journal:  Otolaryngol Clin North Am       Date:  1993-10       Impact factor: 3.346

Review 6.  Animal ototoxicity of topical antibiotics and the relevance to clinical treatment of human subjects.

Authors:  Peter S Roland; Leonard Rybak; Maureen Hannley; Greg Matz; Michael G Stewart; Spiros Manolidis; Rick Friedman; Peter Weber; Fred Owens
Journal:  Otolaryngol Head Neck Surg       Date:  2004-03       Impact factor: 3.497

7.  History of the development of rifampin.

Authors:  P Sensi
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

8.  Formation of free radicals by gentamicin and iron and evidence for an iron/gentamicin complex.

Authors:  E M Priuska; J Schacht
Journal:  Biochem Pharmacol       Date:  1995-11-27       Impact factor: 5.858

9.  High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.

Authors:  Martin J Boeree; Norbert Heinrich; Rob Aarnoutse; Andreas H Diacon; Rodney Dawson; Sunita Rehal; Gibson S Kibiki; Gavin Churchyard; Ian Sanne; Nyanda E Ntinginya; Lilian T Minja; Robert D Hunt; Salome Charalambous; Madeleine Hanekom; Hadija H Semvua; Stellah G Mpagama; Christina Manyama; Bariki Mtafya; Klaus Reither; Robert S Wallis; Amour Venter; Kim Narunsky; Anka Mekota; Sonja Henne; Angela Colbers; Georgette Plemper van Balen; Stephen H Gillespie; Patrick P J Phillips; Michael Hoelscher
Journal:  Lancet Infect Dis       Date:  2016-10-26       Impact factor: 25.071

10.  Classical Presentation of Acute Pyelonephritis in a Case of Brucellosis.

Authors:  Wadha Alfouzan; Sara Al-Sahali; Hawra'a Sultan; Rita Dhar
Journal:  Case Rep Nephrol Dial       Date:  2016-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.